Since December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
rapidly resulted in a global pandemic with approximately 4 million deaths. Effective oral …

Background New treatments are needed to reduce the risk of progression of coronavirus
disease 2019 (Covid-19). Molnupiravir is an oral, small-molecule antiviral prodrug that is …

Objectives AGILE is a Phase Ib/IIa platform for rapidly evaluating COVID-19 treatments. In
this trial (NCT04746183) we evaluated the safety and optimal dose of molnupiravir in …

Background Safe and effective oral treatments are needed to improve clinical outcomes for
nonhospitalized patients with Covid-19. Molnupiravir is an orally administered, small …

Purpose Immunocompromised patients have a potentially increased risk for progression to
severe COVID-19 and prolonged replication of SARS-CoV-2. This post hoc analysis …

Background Molnupiravir is an oral antiviral drug that received Emergency Use
Authorization in three countries for the treatment of mild COVID-19. The aim of this …

ABSTRACT Molnupiravir (EIDD-2801/MK-4482), the prodrug of the active antiviral
ribonucleoside analog β-d-N4-hydroxycytidine (NHC; EIDD-1931), has activity against a …

Background Throughout the time of the global pandemic of SARS-CoV-2 virus, there has
been a compelling necessity for the development of effective antiviral agents and …

Despite the progress in the management of COVID-19, effective oral antiviral agents are still
lacking. In the present review, the potential beneficial effects of molnupiravir in the …

Introduction At present, there are some differences in the research results of molnupiravir.
The purpose of this study was to evaluate the efficacy and safety of molnupiravir in the …